AIFA Funds Nucala for Uncontrolled COPD as Trial Data Shows Fewer Flare-Ups
Patients battling chronic obstructive pulmonary disease face a stark reality when standard inhalers fail, experiencing an average of 1.01 moderate or severe flare-ups annually while on triple therapy. Now, a newly active monitoring registry operated by the Italian medicines agency AIFA since October 31, 2026, changes that math for a specific subset of sufferers, mondosanita.it reported.
The agency’s official communication, published on November 2, 2026, makes the monoclonal antibody Nucala, known generically as mepolizumab, available at the expense of the national health service. Funded access targets adults whose disease remains uncontrolled despite the simultaneous use of three inhaled medications: an inhaled corticosteroid, a long-acting beta2-agonist, and a long-acting muscarinic antagonist.
Blood Eosinophil Levels Dictate Treatment Eligibility
Prescription access requires distinct clinical criteria beyond a standard diagnosis of chronic obstructive pulmonary disease or persistent breathing difficulties. Authorized centers must verify that patients exhibit an elevated count of eosinophils, a specific type of white blood cell that drives airway inflammation by releasing interleukin-5, the exact target that mepolizumab blocks.
This biological treatment does not apply to all individuals with the condition, which is frequently linked to tobacco smoke and environmental pollutants. The therapy is strictly reserved for patients who continue to deteriorate despite adhering to intensive triple-inhaler regimens, preventing broad distribution across the wider patient population.
Evidence supporting the rollout stems from the international MATINEE study published in the New England Journal of Medicine in 2025. The trial tracked 804 participants with elevated eosinophils and frequent flare-ups, administering mepolizumab to roughly half the cohort alongside their standard treatments while the control group received a placebo.
Patients receiving the monoclonal antibody averaged 0.80 moderate or severe flare-ups per year, compared to 1.01 in the placebo group. This represents a relative reduction of 21 percent, or about 21 fewer flare-ups for every one hundred patients treated over twelve months, while median time to the first flare-up extended from 321 days to 419 days.
Trial data revealed no statistically significant improvements in overall quality of life scores, symptom relief, or patient mortality. The biologic does not reverse existing lung damage or cure the underlying condition, leaving emergency room visits and hospital admissions as an open question to be measured through real-world clinical use in Italy.
Registry Monitoring and the Principle of Value-Based Spending
Because biological drugs carry substantial costs, the AIFA monitoring registry aims to connect pharmaceutical spending directly to real-world health outcomes under a value-based care model. The tracking system evaluates how many acute episodes are avoided, how patient hospitalizations shift, and how overall healthcare costs change as clinicians treat eligible adults through specialized centers.
This targeted approach sits alongside foundational care measures that remain essential for all patients. Smoking cessation, correct inhaler technique, pulmonary rehabilitation, recommended vaccinations, and early diagnosis through spirometry continue to form the backbone of chronic respiratory disease management alongside new targeted therapies.
Worth a look